Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
|Videos|November 6, 2018
Can Circulating Tumor DNA Inform Breast Cancer Treatment?
Author(s)Minetta C. Liu, MD
In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.
Advertisement
In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.
Advertisement
Related to this article
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
4
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
5